Nature Communications (Nov 2022)
Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential
- Jeroen Kneppers,
- Tesa M. Severson,
- Joseph C. Siefert,
- Pieter Schol,
- Stacey E. P. Joosten,
- Ivan Pak Lok Yu,
- Chia-Chi Flora Huang,
- Tunç Morova,
- Umut Berkay Altıntaş,
- Claudia Giambartolomei,
- Ji-Heui Seo,
- Sylvan C. Baca,
- Isa Carneiro,
- Eldon Emberly,
- Bogdan Pasaniuc,
- Carmen Jerónimo,
- Rui Henrique,
- Matthew L. Freedman,
- Lodewyk F. A. Wessels,
- Nathan A. Lack,
- Andries M. Bergman,
- Wilbert Zwart
Affiliations
- Jeroen Kneppers
- Division of Oncogenomics, Oncode Institute, Netherlands Cancer Institute
- Tesa M. Severson
- Division of Oncogenomics, Oncode Institute, Netherlands Cancer Institute
- Joseph C. Siefert
- Division of Oncogenomics, Oncode Institute, Netherlands Cancer Institute
- Pieter Schol
- Division of Oncogenomics, Oncode Institute, Netherlands Cancer Institute
- Stacey E. P. Joosten
- Division of Oncogenomics, Oncode Institute, Netherlands Cancer Institute
- Ivan Pak Lok Yu
- Vancouver Prostate Centre, Department of Urologic Science, University of British Columbia
- Chia-Chi Flora Huang
- Vancouver Prostate Centre, Department of Urologic Science, University of British Columbia
- Tunç Morova
- Vancouver Prostate Centre, Department of Urologic Science, University of British Columbia
- Umut Berkay Altıntaş
- School of Medicine, Koç University
- Claudia Giambartolomei
- Central RNA Lab, Istituto Italiano di Tecnologia
- Ji-Heui Seo
- Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California Los Angeles
- Sylvan C. Baca
- The Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute
- Isa Carneiro
- Department of Pathology, Cancer Biology and Epigenetics Group, Portuguese Oncology Institute of Porto and Porto Comprehensive Cancer Center
- Eldon Emberly
- Department of Physics, Simon Fraser University
- Bogdan Pasaniuc
- Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California Los Angeles
- Carmen Jerónimo
- Department of Pathology, Cancer Biology and Epigenetics Group, Portuguese Oncology Institute of Porto and Porto Comprehensive Cancer Center
- Rui Henrique
- Department of Pathology, Cancer Biology and Epigenetics Group, Portuguese Oncology Institute of Porto and Porto Comprehensive Cancer Center
- Matthew L. Freedman
- The Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute
- Lodewyk F. A. Wessels
- Division of Molecular Carcinogenesis, Oncode Institute, Netherlands Cancer Institute
- Nathan A. Lack
- Vancouver Prostate Centre, Department of Urologic Science, University of British Columbia
- Andries M. Bergman
- Division of Oncogenomics, Oncode Institute, Netherlands Cancer Institute
- Wilbert Zwart
- Division of Oncogenomics, Oncode Institute, Netherlands Cancer Institute
- DOI
- https://doi.org/10.1038/s41467-022-35135-2
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 16
Abstract
Epigenetic reprogramming of the androgen receptor (AR) has been identified as an important process driving prostate cancer (PCa) progression. Here, the authors analyze the role of AR chromatin binding heterogeneity in PCa clinical outcomes, metastasis and relapse.
